

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 8, 2025

PE anti-human CD366 (Tim-3)

RRID:AB_2116576

Type: Antibody

Proper Citation

(BioLegend Cat# 345006, RRID:AB_2116576)

Antibody Information

URL: http://antibodyregistry.org/AB_2116576

Proper Citation: (BioLegend Cat# 345006, RRID:AB_2116576)

Target Antigen: CD366

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD366 (Tim-3)

Description: This monoclonal targets CD366

Target Organism: human

Clone ID: Clone F38-2E2

Antibody ID: AB_2116576

Vendor: BioLegend

Catalog Number: 345006

Alternative Catalog Numbers: 345005

Record Creation Time: 20231110T051517+0000

Record Last Update: 20241115T060721+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD366 (Tim-3).

No alerts have been found for PE anti-human CD366 (Tim-3).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. *Cell metabolism*, 36(1), 176.

Wang Z, et al. (2024) Suppression of the METTL3-m6A-integrin $\alpha 1$ axis by extracellular acidification impairs T cell infiltration and antitumor activity. *Cell reports*, 43(2), 113796.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Huang Y, et al. (2024) Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. *Cell reports. Medicine*, 5(2), 101400.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. *Cell reports. Medicine*, 4(2), 100917.

Tamura T, et al. (2023) Single-cell transcriptomics reveal a hyperacute cytokine and immune checkpoint axis after cardiac arrest in patients with poor neurological outcome. *Med (New York, N.Y.)*, 4(7), 432.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8⁺ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.

Jung IY, et al. (2023) Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. *Cell reports. Medicine*, 4(6), 101053.

Ducoin K, et al. (2022) Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. *Cancers*, 14(17).

Ceppi F, et al. (2022) Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. *Cancer immunology research*, 10(7), 856.

Ducoin K, et al. (2022) Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. *Oncoimmunology*, 11(1), 2046931.

Srivastava S, et al. (2021) Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. *Cancer cell*, 39(2), 193.

Houtsma R, et al. (2021) CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones. *STAR protocols*, 2(4), 100864.

de Boer B, et al. (2018) Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. *Cancer cell*, 34(4), 674.